...
首页> 外文期刊>Zeitschrift fur Gastroenterologie >Economic aspects of inpatient treatment for decompensated liver cirrhosis: A prospective study employing an evidence-based clinical pathway [Gesundheits?konomische Aspekte der station?ren Behandlung von Patienten mit dekompensierter Leberzirrhose: eine prospektive Studie unter Nutzung eines evidenzbasierten Behandlungspfads]
【24h】

Economic aspects of inpatient treatment for decompensated liver cirrhosis: A prospective study employing an evidence-based clinical pathway [Gesundheits?konomische Aspekte der station?ren Behandlung von Patienten mit dekompensierter Leberzirrhose: eine prospektive Studie unter Nutzung eines evidenzbasierten Behandlungspfads]

机译:代偿性肝硬化住院治疗的经济方面:一项采用循证临床途径的前瞻性研究

获取原文
获取原文并翻译 | 示例
           

摘要

The introduction of the G-DRG reimbursement system has greatly increased the pressure to provide cost effective treatment in German hospitals. Reimbursement based on diagnosis-related groups, which requires stratification of costs incurred is still not sufficiently discriminating the disease severity and severity in relation to the intensive costs in gastroenterology. In a combined retrospective and prospective study at a tertial referral centre we investigated whether this also applies for decompensated liver cirrhosis. In 2006, 64 retrospective cases (age 57 ?? 12.9; ?? 69.2 %, ?? 29.8 %) with decompensated liver cirrhosis (ICD code K76.4) were evaluated for their length of hospitalisation, reimbursement as well as Child and MELD scores. In 2008, 74 cases with decompensated liver cirrhosis were treated in a prospective study according to a standardised and evidence-based clinical pathway (age 57 ?? 12.2; 73 % ??, ?? 27 %). Besides a trend in the reduction of length of hospital stay (retrospective: 13.6 ?? 8.6, prospective 13.0 ?? 7.2, p = 0.85) overall revenues from patients treated according to a evidence-based clinical pathway were lower than the calculated costs from the InEK matrix. Costs of medication as a percentage of reimbursement amount increased with increasing severity. In both years we could demonstrate an inverse correlation between daily reimbursement and disease severity which precluded cost coverage. For the cost-covering hospital treatment of patients with decompensated liver cirrhosis an adjustment of the DRG based on clinical severity scores such as Child-Pugh or MELD is warranted, if evidence-based treatment standards are to be kept. ? 2013 Georg Thieme Verlag KG Stuttgart New York.
机译:G-DRG报销系统的引入大大增加了在德国医院中提供具有成本效益的治疗的压力。基于诊断相关人群的报销(需要对费用进行分层)仍无法充分区分疾病严重程度和严重程度,而与胃肠病学的高昂费用相关。在三级转诊中心进行的一项回顾性和前瞻性研究中,我们调查了这是否也适用于失代偿性肝硬化。 2006年,对64例失代偿性肝硬化(ICD代码K76.4)的回顾性病例(57岁12.9岁; 69.2%≥29.8%)进行了住院,报销以及Child和MELD评分的评估。 2008年,根据一项标准化和循证的临床途径(前瞻性研究),对74例失代偿性肝硬化患者进行了前瞻性研究(年龄57岁12.2岁; 73%为27​​%)。除了住院时间减少的趋势(回顾性:13.6±8.6,前瞻性13.0±7.2,p = 0.85)以外,根据循证临床途径治疗的患者的总收入也低于根据InEK矩阵。药物费用占报销金额的百分比随着严重程度的增加而增加。在这两年中,我们都可以证明每日报销与疾病严重程度之间存在反相关关系,因此无法支付费用。对于需要补偿费用的住院治疗失代偿性肝硬化患者,如果要保留循证治疗标准,则有必要根据Child-Pugh或MELD等临床严重性评分对DRG进行调整。 ? 2013 Georg Thieme Verlag KG斯图加特纽约。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号